FWBI
NASDAQFirst Wave BioPharma Inc.
Latest news
25 items- NEWSFirst Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac DiseaseEntero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today unveiled its new corporate name and website. The rebranding follows the recent business combination with ImmunogenX and reflect the Company's focus on addressing unmet needs in GI health that include celiac disease, an indication for which there are no approved medicines today. Entero's common stock will commence trading on May 17, 2024, on the Nasdaq Capital Market under the new ticker symbol of ENTO.
- SECFirst Wave BioPharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - First Wave BioPharma, Inc. (0001604191) (Filer)
- PRFirst Wave BioPharma Changes Name to Entero TherapeuticsRebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is "ENTO" effective May 17, 2024 BOCA RATON, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today unveiled its new corporate name and website. The rebranding follows the recent business combination with ImmunogenX and reflect the Company's focus on addressing unmet needs in GI health
- SECSEC Form 10-Q filed by First Wave BioPharma Inc.10-Q - First Wave BioPharma, Inc. (0001604191) (Filer)
- SECFirst Wave BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - First Wave BioPharma, Inc. (0001604191) (Filer)
- SECSEC Form 424B5 filed by First Wave BioPharma Inc.424B5 - First Wave BioPharma, Inc. (0001604191) (Filer)
- NEWSFirst Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The MarketFirst Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 366,000 shares of the Company's common stock (or common stock equivalents) at a price of $2.95 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 732,000 shares of common
- PRFirst Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketBOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 366,000 shares of the Company's common stock (or common stock equivalents) at a price of $2.95 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the invest
- PRFirst Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness MonthBOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that in honor of Celiac Disease Awareness Month in May, it will partner with Celiac Journey, a celiac disease patient advocacy organization, to share an awareness digital display on the Nasdaq Tower in Times Square on Thursday, May 16, at 4:25 p.m. ET. The digital display will also be shown at night as part of the international "Shine a Light on Celiac Disease" initiative to illuminate famous la
- SECFirst Wave BioPharma Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)8-K/A - First Wave BioPharma, Inc. (0001604191) (Filer)
- NEWSFirst Wave Biopharma Announced Research Generated From Two Previously Completed Phase 2 Clinical Trials Of Latiglutenase Has Been Published In The Special Issue In The Peer-reviewed Scientific Journal
- PRFirst Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsBOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced research generated from two previously completed Phase 2 clinical trials of latiglutenase has been published in the special issue "Recent Advances in Gluten-Free Diet and Celiac Disease" in the peer-reviewed scientific journal, Nutrients. Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic f
- PRFirst Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseBOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Planet MicroCap Showcase, which will be held April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas. Details of the event are as follows: Event:Planet MicroCap ShowcaseDate: Wednesday, May 1, 2024Time:11:30 am – 12:00 pm PDTLocation:Paris Hotel & Casino, Las VegasRegistration:https://planetmicroca
- PRFirst Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceBOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will participate in the Longwood Healthcare Leaders Conference, which will be held April 29 - May 1, 2024 at The Ritz-Carlton in Key Biscayne, Florida. Details of the event are as follows: Event:Longwood Healthcare Leaders ConferenceDate: April 29 – May 1, 2024Location:The Ritz-Carlton, Key Biscayne, FLRegistration:https://www.l
- INSIDERSapirstein James sold $736 worth of shares (174 units at $4.23), decreasing direct ownership by 0.47% to 37,105 units (SEC Form 4)4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
- INSIDERRomano Sarah sold $317 worth of shares (75 units at $4.23), decreasing direct ownership by 0.39% to 19,111 units (SEC Form 4)4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
- SECSEC Form 10-K filed by First Wave BioPharma Inc.10-K - First Wave BioPharma, Inc. (0001604191) (Filer)
- NEWSHC Wainwright & Co. Reinstates Neutral on First Wave BioPharmaHC Wainwright & Co. analyst Yi Chen reinstates First Wave BioPharma (NASDAQ:FWBI) with a Neutral.
- SECFirst Wave BioPharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - First Wave BioPharma, Inc. (0001604191) (Filer)
- INSIDERSapirstein James sold $9,360 worth of shares (1,887 units at $4.96), decreasing direct ownership by 5% to 37,279 units (SEC Form 4)4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
- INSIDERRomano Sarah sold $5,555 worth of shares (1,120 units at $4.96), decreasing direct ownership by 6% to 19,186 units (SEC Form 4)4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
- SECFirst Wave BioPharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - First Wave BioPharma, Inc. (0001604191) (Filer)
- SECSEC Form DEFA14A filed by First Wave BioPharma Inc.DEFA14A - First Wave BioPharma, Inc. (0001604191) (Filer)
- PRFirst Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferencePoster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion diagnostics for identifying seroactive patients and for monitoring the efficacy of Latiglutenase, the Company's Celiac Disease therapeutic program BOCA RATON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that two abstracts have been accepted for presentation
- INSIDERSyage Jack was granted 15,400 shares (SEC Form 4)4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
FWBI FAQ
6 questionsWhere does FWBI stock trade?
First Wave BioPharma Inc. (FWBI) is listed on NASDAQ.What sector and industry is FWBI in?
First Wave BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did First Wave BioPharma Inc. go public?
First Wave BioPharma Inc. (FWBI) completed its IPO in 2016.What are analysts saying about FWBI?
First Wave BioPharma Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Hold on 2021-12-07.What companies are similar to FWBI?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare FWBI side-by-side with any of them on Quantisnow.How can I track FWBI on Quantisnow?
Quantisnow aggregates First Wave BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FWBI to receive live email and push alerts on every new disclosure.